The Brain Tumor Investment Fund is a growing and diverse venture philanthropy fund that leverages the National Brain Tumor Society’s (NBTS) 30 years of experience, expertise, and achievement. The fund will support NBTS’s vision to conquer and cure brain tumors by investing in biotechnology, pharmaceutical, and medical device companies developing products to improve the lives of brain tumor patients.
The Brain Tumor Investment Fund sparks private sector investment in brain tumor research and to create a robust and diverse market for drug development, while increasing the likelihood of success for companies bringing life-changing products to market.
It is a pivotal moment. New platform technologies and therapeutic modalities can target previously considered undruggable targets, allowing for the development of novel therapeutics and diagnostics that were unthinkable and unachievable 10 years ago. New scientific discoveries are transforming our mechanistic understanding of brain tumor vulnerabilities, and the number of brain tumor spin-out companies is rising (most of them being within the NBTS network), offering a unique opportunity to invest in a growing market. In fact, it is estimated that the global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to $2 billion by 20231.
live with a primary brain tumor
will receive a primary brain tumor diagnosis in 2022
is the five-year relative survival rate for all malignant brain tumor patients
will die from a malignant brain tumor in 2022
The Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, is the convener and a catalyst for private sector investment, led by a distinguished team of experts with deep experience in brain tumor research and drug development.
Vanessa Almendro, PhD, MBA
Vice President of Science and Technology at Danaher Corporation
Vanessa has more than 18 years of leadership experience in translational research and drug development in a broad spectrum of common and rare disease areas. She has a PhD from the University of Barcelona, Post-doctoral training from Dana-Farber Cancer Institute and Harvard Medical School, and an Executive MBA from MIT Sloan School of Management.
Scientific Advisory Council Lead
Kirk Tanner, PhD
Senior Vice President, Brain Tumor Investment Fund
Chief Scientific Officer at the National Brain Tumor Society
Kirk is an oncology research leader with two decades of experience in discovery and development projects and programs resulting in multiple clinical candidate therapies and investigational new drugs. He leads the National Brain Tumor Society’s research program that aims to catalyze treatment development through philanthropic investment in medical research, engaging scientists, clinicians, patients, and care partners in research programs.
Yury Kukushkin, PhD
Managing Director, JDRF, T1D Fund
Co-founder, Future Biotech
Prior to this role, Yury was a Principal and later Venture Partner at 4BIO Capital, a London-based fund investing in public and private life sciences companies. Prior to this role, he was Chief Analyst and Associate at RBV Capital, an early-stage life sciences venture fund. Originally from Moscow, Russia, Yury received his M.S. in Biochemistry with specialization in Virology from Moscow State University and a Ph.D. in Cellular Biochemistry from Max Planck Institute of Biochemistry, Martinsried, Germany.
John Frishkopf, MMS
CEO, Klocke Estate; Partner, QLS Advisors
John is a founder of NewStar Financial, Inc., from which he retired as Treasurer and Head of Asset Management. A graduate of MIT and MIT Sloan, John Frishkopf has spoken at conferences and has published on using financial engineering techniques to speed the drug discovery process. John served on the NBTS Board for seven years to honor the life of his late husband, David King, who passed away in 2014 from GBM.
Eric Olson, PhD
Chief Scientific Officer at Syros Pharmaceuticals
Eric has over 30 years of experience in the life sciences industry, most recently as Research Vice President for respiratory diseases at Vertex Pharmaceuticals. During his 12 years at Vertex, he led research, development, and commercial teams in bringing to patients the first cystic fibrosis (CF) treatment resulting from discovery of the CF gene.
David Arons, JD
President and Chief Executive Officer of the National Brain Tumor Society
David previously served in leadership and external positions at the American Cancer Society in Minnesota, the Center for Lobbying in the Public Interest, and in the Independent Sector. As an attorney, he previously represented patients facing disabilities and serious health conditions. He has previously served on then Vice President Biden’s Cancer Moonshot Blue Ribbon Panel, as Chair of the National Cancer Institute’s Council of Research Advocates and as a Member of its Clinical Trials Advisory Committee.
Tom Roloff, MBA
Former Senior Vice President of Information Technology & Business Transformation at Dell Technologies Corporation
Tom was also a vice president of EMC and Chief Operating Officer at EMC Consulting. He has also held senior management positions at Perot Systems and HomeLife Medical. He earned his undergraduate degree at Lafayette University, a master’s degree at Virginia Tech University, and an MBA from MIT Sloan School of Management.
Michelle Barton, PhD
Michelle (Shelley) Barton is a Co-Director of the Cancer Early Detection Advanced Research (CEDAR) center and professor in the Division of Oncological Sciences at the Knight Cancer Institute, Oregon Health & Science University (OHSU) in Portland, OR. Prior to CEDAR, she was a professor and Dean for Graduate Studies in the Department of Epigenetics and Molecular Carcinogenesis at the MD Anderson Cancer Center in Houston, TX. Shelley’s research areas of interest are epigenetics, p53 signaling and breast cancer.
Manmeet Ahluwalia, MD, MBA
Manmeet serves as the Deputy Director, Chief of Medical Oncology, Chief Scientific Officer, Miami Cancer Institute, Miami, Florida, where he subspecializes in treatment of patients with brain tumors and brain metastases. His research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well immunotherapeutic approaches.
Ranjit S. Bindra, MD, PhD
Ranjit is a Yale University Harvey and Kate Cushing Professor of Therapeutic Radiology Vice Chair, Translational Research & Therapeutic Radiology and Scientific Director at Chênevert Family Brain Tumor Center. A physician-scientist and an entrepreneur, Dr. Bindra feels a deep commitment to improve the lives of cancer patients. At Yale Cancer Center, Dr. Bindra treats adult and pediatric patients with primary CNS brain tumors and cancer metastases. At Yale, Ranjit manages research focused on synthetic lethal screening strategies to exploit DNA repair defects in cancer and translates the results into Phase I and II clinical trials. A serial biotech entrepreneur with passion for developing oncology therapeutics, Bindra has co-founded several companies: Cybrexa Therapeutics, Alphina Therapeutics, B3 Therapeutics, and Modifi Bio.
Frederick F. Lang, MD
Frederick is professor and chairman of the Department of Neurosurgery at MD Anderson. He is Co-Director of the MD Anderson Brain Tumor Center and Co-Leader of the GBM Moon Shot. He is the Principal Investigator on MD Anderson’s SPORE in Brain Cancer. He is a NIH-funded translational researcher focused on developing novel biological therapies. He is past president of the Society of Neuro-oncology and past chair of the CNS/AANS Section on Tumors. He is the recipient of numerous awards and honors, including America’s Top Doctors for Cancer, the Preuss Research Award, the Mahaley Award, and the Otis W. and Pearl Walters Faculty Achievement Award in Clinical Research.
Mariella Gruber Filbin, MD, PhD
Mariella is a Pediatric Neuro-oncologist and Principal Investigator at Dana-Farber Cancer Institute (DFCI) and Boston Children’s Hospital (BCH), Co-Director of the Brain Tumor Center for Excellence at DFCI/BCH, and an Assistant Professor in Pediatrics at Harvard Medical School. Her research focuses on pediatric brain tumors, particularly high-grade gliomas and malignant embryonal brain tumors. She is combining single-cell genetics and transcriptomics with gene editing, epigenetic, stem cell, and pharmacologic methods to identify networks underlying tumorigenesis.
Len Post, PhD
Len’s experience spans 30 years and all stages of drug development, from early discovery through FDA approval with a focus on oncology and genetic diseases. Len was a founder of LEAD Therapeutics, which led to the discovery of Talazoparib, and was later acquired by BioMarin Pharmaceuticals where he served as the Chief Scientific Officer. His current position is Chief Scientific Officer of Vivace Therapeutics and Virtuoso Therapeutics. Len received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Biochemistry from the University of Wisconsin, Madison.